previous arrow
next arrow


路明克斯公司的xTAG™ 和 MultiCode®-RTx 技术灵敏度及准确性高,应用领域广泛,适用于高通量及高速度的检测。





Become a Partner

Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology.
Click here to start the conversation now.


Luminex Blog

Luminex Licensed Technologies Partner Spotlight: EpiCypher

EpiCypher delivers high-quality reagents for epigenetics and chromatin research

As one of Luminex’s Licensed Technologies Partners, EpiCypher is one of many companies that uses xMAP® Technology to deliver important solutions for improving research and molecular diagnostics. Based out of the Research Triangle Park in North Carolina, EpiCypher is a biotechnology company that helps scientists push the boundaries of research in chromatin regulation, chromatin mapping, and epigenetics.

Continue Reading >




xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.

Luminex on Twitter

The @US_FDA has approved the drug Veklury (Remdesivir) for the treatment of COVID-19 requiring hospitalization. It is the first treatment to receive FDA approval. Read more here:
h J R
@IDSE_Online: Using a rapid molecular diagnostic assay to identify VRE cut in-hospital mortality rates by nearly 80%. @UTexasPharmacy @Luminex #rapiddiagnostics #IDWeek2020
h J R
In this new @FrontImmunol study, multiplex immunoassays offer advantages for measuring cytokines in human plasma, which can be useful in diagnosing, tracking, & treating health disorders. Read the study here:
h J R